361 related articles for article (PubMed ID: 29381102)
1. Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments.
Gnutzmann D; Kortes N; Sumkauskaite M; Schmitz A; Weiss KH; Radeleff B
Minim Invasive Ther Allied Technol; 2018 Apr; 27(2):69-80. PubMed ID: 29381102
[TBL] [Abstract][Full Text] [Related]
2. [Transarterial ablation of hepatocellular carcinoma. Status and developments].
Radeleff BA; Stampfl U; Sommer CM; Bellemann N; Hoffmann K; Ganten T; Ehehalt R; Kauczor HU
Radiologe; 2012 Jan; 52(1):44-55. PubMed ID: 22249701
[TBL] [Abstract][Full Text] [Related]
3. HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer.
Vogl TJ; Gruber-Rouh T
Dig Dis Sci; 2019 Apr; 64(4):959-967. PubMed ID: 30835030
[TBL] [Abstract][Full Text] [Related]
4. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.
Facciorusso A
World J Gastroenterol; 2018 Jan; 24(2):161-169. PubMed ID: 29375202
[TBL] [Abstract][Full Text] [Related]
5. New concepts in embolotherapy of HCC.
Pesapane F; Nezami N; Patella F; Geschwind JF
Med Oncol; 2017 Apr; 34(4):58. PubMed ID: 28299645
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma Post Embolotherapy: Imaging Appearances and Pitfalls on Computed Tomography and Magnetic Resonance Imaging.
Chiu RY; Yap WW; Patel R; Liu D; Klass D; Harris AC
Can Assoc Radiol J; 2016 May; 67(2):158-72. PubMed ID: 26961737
[TBL] [Abstract][Full Text] [Related]
7. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis.
Zou JH; Zhang L; Ren ZG; Ye SL
J Dig Dis; 2016 Aug; 17(8):510-517. PubMed ID: 27384075
[TBL] [Abstract][Full Text] [Related]
9. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
Lee EW; Khan S
Clin Mol Hepatol; 2017 Dec; 23(4):265-272. PubMed ID: 29113030
[TBL] [Abstract][Full Text] [Related]
11. [Survival benefit with intraarterial techniques in hepatocellular carcinoma].
Sangro B
Gastroenterol Hepatol; 2014 Jul; 37 Suppl 2():95-101. PubMed ID: 25087719
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
13. Chemoembolization and radioembolization.
Sangro B
Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):909-19. PubMed ID: 25260317
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
[TBL] [Abstract][Full Text] [Related]
15. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.
Lee YK; Jung KS; Kim DY; Choi JY; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim GM; Kim MD; Park SI; Won JY; Lee DY
J Gastroenterol Hepatol; 2017 Feb; 32(2):487-496. PubMed ID: 27503585
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma.
Cucchetti A; Trevisani F; Cappelli A; Mosconi C; Renzulli M; Pinna AD; Golfieri R
Dig Liver Dis; 2016 Jul; 48(7):798-805. PubMed ID: 27263056
[TBL] [Abstract][Full Text] [Related]
17. Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads.
Maschke SK; Werncke T; Klöckner R; Rodt T; Renne J; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
Abdom Radiol (NY); 2018 May; 43(5):1245-1253. PubMed ID: 28840307
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices.
Fohlen A; Tasu JP; Kobeiter H; Bartoli JM; Pelage JP; Guiu B
Diagn Interv Imaging; 2018 Sep; 99(9):527-535. PubMed ID: 29609903
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma.
Nam HC; Jang B; Song MJ
World J Gastroenterol; 2016 Oct; 22(40):8853-8861. PubMed ID: 27833376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
